This is a contrast between Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) and Madrigal Pharmaceuticals Inc. (NASDAQ:MDGL) based on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. The two companies are Biotechnology and they also compete with each other.

Valuation and Earnings

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Vanda Pharmaceuticals Inc.	193.12M	5.14	25.21M	0.47	42.39
Madrigal Pharmaceuticals Inc.	N/A	0.00	32.81M	-2.13	0.00

Table 1 demonstrates Vanda Pharmaceuticals Inc. and Madrigal Pharmaceuticals Inc.’s gross revenue, earnings per share and valuation.

Profitability

Table 2 has Vanda Pharmaceuticals Inc. and Madrigal Pharmaceuticals Inc.’s return on equity, return on assets and net margins.

	Net Margins	Return on Equity	Return on Assets
Vanda Pharmaceuticals Inc.	13.05%	9.8%	8%
Madrigal Pharmaceuticals Inc.	0.00%	0%	0%

Volatility and Risk

Vanda Pharmaceuticals Inc.’s 0.51 beta indicates that its volatility is 49.00% less volatile than that of Standard and Poor’s 500. From a competition point of view, Madrigal Pharmaceuticals Inc. has a 1.23 beta which is 23.00% more volatile compared to Standard and Poor’s 500.

Liquidity

Vanda Pharmaceuticals Inc. has a Current Ratio of 5.6 and a Quick Ratio of 5.6. Competitively, Madrigal Pharmaceuticals Inc.’s Current Ratio is 57.5 and has 57.5 Quick Ratio. Madrigal Pharmaceuticals Inc.’s better ability to pay short and long-term obligations than Vanda Pharmaceuticals Inc.

Analyst Recommendations

Ratings and Recommendations for Vanda Pharmaceuticals Inc. and Madrigal Pharmaceuticals Inc. can be find in next table.

	Sell Ratings	Hold Ratings	Buy Ratings	Rating Score
Vanda Pharmaceuticals Inc.	0	2	4	2.67
Madrigal Pharmaceuticals Inc.	0	0	0	0.00

The consensus price target of Vanda Pharmaceuticals Inc. is $40.17, with potential upside of 113.10%.

Insider and Institutional Ownership

Roughly 0% of Vanda Pharmaceuticals Inc. shares are owned by institutional investors while 95.7% of Madrigal Pharmaceuticals Inc. are owned by institutional investors. Insiders owned roughly 3.1% of Vanda Pharmaceuticals Inc.’s shares. Insiders Competitively, owned 3.2% of Madrigal Pharmaceuticals Inc. shares.

Performance

Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

	Performance (W)	Performance (M)	Performance (Q)	Performance (HY)	Performance (Y)	Performance (YTD)
Vanda Pharmaceuticals Inc.	-3.88%	-26.87%	-17.51%	-2.51%	6.1%	-24.07%
Madrigal Pharmaceuticals Inc.	1.75%	19.8%	20.7%	-42.37%	11.43%	23.03%

For the past year Vanda Pharmaceuticals Inc. had bearish trend while Madrigal Pharmaceuticals Inc. had bullish trend.

Summary

On 9 of the 11 factors Vanda Pharmaceuticals Inc. beats Madrigal Pharmaceuticals Inc.

Vanda Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of products for the treatment of central nervous system disorders. The companyÂ’s marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorder; and Fanapt (iloperidone), a product for the treatment of schizophrenia. Its clinical development products include Tradipitant (VLY-686), a small molecule neurokinin-1 receptor antagonist that is under the clinical development for the treatment of chronic pruritus in atopic dermatitis and gastroparesis; Trichostatin A, a small molecule histone deacetylase inhibitor, which is in development for the treatment of hematologic malignancies; and AQW051, a Phase II alpha-7 nicotinic acetylcholine receptor partial agonist. The company markets its products in the United States, Canada, Europe Union, Israel, and Mexico. Vanda Pharmaceuticals Inc. was incorporated in 2002 and is headquartered in Washington, the District of Columbia.

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutic candidates for the treatment of cardiovascular, metabolic, and liver diseases. The company’s lead candidate is MGL-3196, which is in Phase II clinical trials, a liver-directed thyroid hormone receptor-ß (THR-ß) agonist used for the treatment of nonalcoholic fatty liver disease, nonalcoholic steatohepatitis, and familial hypercholesterolemia. It is also developing MGL-3745, which is in pre-clinical stage, a THR-ß agonist that is in preclinical trials. The company was founded in 2011 and is headquartered in West Conshohocken, Pennsylvania.